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Abstract 
 
Background. Poorly differentiated follicular carcinomas (PDFC) of the thyroid 
represent an heterogeneous but distinct group of tumors, clinically and 
histopathogenetically intermediate between follicular-derived well-
differentiated and anaplastic carcinomas. The existence of this group of tumors 
was first proposed independently by Sakamoto et al. in 1983 and  Carcangiu et 
al. in 1984 according to substantially different diagnostic criteria. Indeed, 
although the number of articles written on the subject of PD carcinoma has 
grown exponentially during the last decade, at the present the diagnostic 
criteria differ between  various authors. Moreover, there is no clear definition 
of the histological, immunohistochemical and genetic characteristics of PDFC. 
Furthermore, although the majority of studies show the aggressiveness of 
PDFC with a high propensity for local recurrence and distant metastasis, there 
is no consensus regarding the prognostic indicators for these tumors. 
Objective:  The work performed during my Doctorate thesis in France 
contributes to clarify the histological definition and to identify clinical, 
histological, immunohistochemical characteristics of PDFC. For this purpose, 
parallel clinical, histological and immunohistochemical investigations have 
been performed.  
Methods: Forty patients affected by PDFC were identified on the basis of a 
trabecular, insular, or solid (TIS) growth pattern, and their clinical outcome 
was correlated with histological architecture, cytological characteristics and 
expression of various markers of cell proliferation and differentiation such as 
cyclin A, B1, D1 and E, Ki67, TPO, galectin 3, Duox, VEGF, EGFR, P53. 
Results: The mean survival was 5.2 ± 5 years. At 5 years,the survival rate was 
63% and the metastasis-free survival rate was 57%. An older age at the time of 
diagnosis and a larger tumor size were associated with an increased risk of 
distant metastases and of cancer related death whereas a high expression of 
Duox was associated with a reduced risk of death. In these patients with PDFC, 
no histological features or marker expression was prognostic. Conclusion: this 
study confirmed that PDFC has a more aggressive behavior than well 
differentiated carcinoma (WDC); prognosis is related to indicators that are 
relevant in patients with WDC, advanced age and larger tumor size. 
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1. INTRODUCTION 
 
Follicular thyroid cells can give rise to both benign and malignant tumors. It is 
estimated that 5-10% of the population will develop a clinically significant 
thyroid nodule during their life time (Mazzaferri 1993). However, thyroid 
cancer is found in less than 5% of thyroid nodules.  
A schematic classification of thyroid tumors is presented in Table 1.  
 
 
Table 1: Classification of thyroid tumors (adapted from Hendinger et al. 
1988) 
 
 
EPITHELIAL THYROID CARCINOMA 
 
Papillary Carcinoma: 
evidence of follicular differentiation with papillary and follicular structures and 
characteristic nuclear changes 
Follicular Carcinoma 
evidence of follicular cell differentiation without the diagnostic features of 
papillary carcinoma 
Undifferentiated (anaplastic) Carcinoma 
A highly malignant tumor composed in part or wholly of undifferentiated cells. 
 
 
C CELL-DERIVED THYROID CARCINOMA 
Medullary carcinoma 
evidence of C cell differentiation 
 
MALIGNANT NON- EPITHELIAL TUMORS 
Sarcoma 
Hemangioendothelioma 
Malignant Lymphoma 
 
SECONDARY TUMORS 
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There are two histological types of epithelial differentiated thyroid cancer, 
papillary or follicular lesions. Papillary carcinomas are the most common, 
accounting for 85% of all thyroid cancers whereas follicular thyroid carcinoma 
(FTC) accounts for approximately 10% of all thyroid malignancies (Parkin et 
al. 1997) Unlike the papillary histologic type, follicular carcinoma usually 
presents as a solitary thyroid tumor. In epidemiological surveys, FTC tends to 
be more common in areas with iodine deficiency. Owing to a combination of 
changing diagnostic criteria and an increased incidence of papillary thyroid 
carcinoma associated with dietary iodine supplementation, the diagnosis of 
FTC is becoming less frequent. The female-male ratio for individuals with FTC 
is 3.3:1.0 and it occurs mostly after the age of 50 years (Grebe and Hay 1995).  
FTC generally is considered to be a more aggressive tumor than PTC and 
lymph node metastases are uncommon in patients with FTC, occurring in 10% 
whereas 50% of patients with papillary thyroid carcinoma have at least 
microscopic lymph node metastases.  Distant pulmonary or bone metastases, 
however, are more common in FTC patients (30%) compared with papillary 
thyroid carcinoma patients (15%) (Mazzaferri et al. 1977, Emerick et al. 1993). 
However, the cancer related mortality is low in well differentiated thyroid 
carcinoma as a consequence of the availability of accurate diagnostic 
techniques, effective treatment and specific protocol of follow up for detecting 
persistent or recurrent disease (Pacini et al 2006, Cooper et al 2006, Pagano  et 
al 2004)  
    
 
1.1 Follicular Thyroid Carcinoma: Definition And Histological 
Classification   
 
1.1.1 Common Histologic type 
 
FTC is defined as "a malignant epithelial tumor showing evidence of follicular 
cell differentiation but lacking the diagnostic features of papillary carcinoma."  
Follicular carcinomas constitute a heterogeneous group of tumors that includes 
tumors with favorable prognosis and tumors with an aggressive behavior. The 
microscopic appearance of FTC varies from well-formed follicles to a 
predominantly solid growth pattern. Poorly formed follicles and atypical patterns 
(e.g., cribriform) may occur, and multiple architectural types may coexist. Mitotic 
activity is not a useful indicator of malignancy. The diagnosis of malignancy 
depends on the demonstration of blood vessel and/or capsular invasion (Brennan 
et al. 1991, Lang et al. 1986, D’Avanzo et al. 2004).  
Indeed, FTCs are classified into two categories based on the degree of 
invasiveness :  
1) minimally invasive or encapsulated 
2) widely invasive.  
This distinction has a significant prognostic impact, since the prognosis is more 
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severe in widely invasive tumors. There is minimal overlapping between these 
two types of FTC. Minimally invasive FTC is an encapsulated tumor whose 
growth pattern resembles that of a trabecular/solid, microfollicular, or atypical 
adenoma. Blood vessel invasion is almost never seen grossly. Microscopically the 
vessels "should be of venous caliber, be located in or immediately outside the 
capsule and contain one or more clusters of tumor cells attached to the wall and 
protruding into the lumen." Rupture of the capsule must concern the entire 
thickness to be considered as capsular invasion. The diagnosis of FTC cannot be 
made if there is penetration of only the inner half or if tumor cells are embedded 
in the capsule. Foci of capsular invasion must be distinguished from capsular 
rupture that can be caused by FNA. Fine-needle biopsy is incapable of 
differentiating benign from malignant lesions and frozen section analysis, even 
with multiple sampling of different areas of the nodule, may still lead to 
misdiagnosis. Examination of multiple blocks including the periphery of the 
nodule is often necessary to exclude or confirm invasion.  
"Widely invasive" FTC may be partially encapsulated, but the margins are 
infiltrative even on gross examination, and vascular invasion is often extensive.  
The structural features are variable with solid and trabecular areas, but a follicular 
element is always present. 
  
1.1.2Hürthle cell carcinoma (oncocytic carcinoma or oxyphilic variant FTC)  
 
It is a tumor composed of more than 75% of cells with oncocytic features. The 
correct classification of Hürthle cell carcinomas is controversial. The WHO 
committee has taken the stance that this tumor is an oxyphillic variant of FTC 
(Hedinger et al. 1988). The AFIP, on the other hand, considers that "the tumors 
made up of this cell type have gross, microscopic, behavioral, cytogenetic (and 
conceivably etiopathogenic) features that set them apart from all others and justify 
discussing them in a separate section” (Rosai et al. 1995).  Macroscopically, the 
oxyphilic variant presents as a solitary thyroid tumor with complete or partial 
encapsulation. The same criteria of malignancy mentioned for follicular tumors 
(i.e. vascular and capsular invasion) also apply to these tumors. Oncocytic 
carcinomas occur at a mean age of about 60 years, are more frequently 
associated with extrathyroid extension and with both distant and lymph-node 
metastases than typical follicular carcinomas. In several series, the prognosis of 
Hürthle cell carcinoma is reported to be similar to that of FTC (Chen et al. 
1998). 
 
1.1.3 Poorly differentiated thyroid carcinoma 
 
When follicular differentiation is poor or absent, the tumor is classified as a 
poorly-differentiated carcinoma (PDFC). WHO classification individualizes the 
poorly differentiated follicular carcinoma (PDFC) defined as "a tumor of 
follicular cell origin with morphological and biologic attributes intermediate 
between differentiated and anaplastic carcinomas of the thyroid” (DeLellis et al. 
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2004). It accounts for approximately 2-4% of all thyroid carcinomas and 
represents a heterogeneous group (Carcangiu et al. 1984, Ashfaq et al 1994, Pilotti 
et al. 1997).  
Insular thyroid carcinoma usually maintains some of the functional characteristics 
of the follicular thyroid cells, such as iodine uptake and thyroglobulin production 
(Carcangiu et al. 1984, Papotti etal. 1993). The most distinctive histologic feature 
is the presence of small cells with round nuclei and scant cytoplasm with a diffuse 
solid pattern or organized in round or oval nests (insulae) or in trabeculae. The 
predominant pattern of growth is solid, but papillary structures or microfollicles 
are also seen. Foci of necrosis, extra-thyroid extension and blood vessel invasion 
are common.  
However, the histological definition of PDFC is still controversial and various 
diagnostic criteria have been proposed (Sakamoto et al 1983, Carcangiu et al. 
1984, Papotti M et al 1993, Hiltzik et al 2006, Volante et al. 2007). Indeed, the 
existence of poorly differentiated thyroid carcinoma was first proposed 
independently by Sakamoto (1983) and by Carcangiu (1984) according to 
substantially different criteria. Sakamoto (1983) relied exclusively on the 
pattern of growth, that is, they regarded as well-differentiated for those tumors 
that had a follicular or a papillary architecture, and as PD those that had (even 
focally) a solid, trabecular, or “scirrhous” architecture. The appearance of the 
nuclei, the mitotic rate, and the presence of necrosis played no role in this 
classification scheme. Conversely, Carcangiu (1984) adopted a much more 
restricted approach: these authors required an insular pattern of growth (hence 
the term “insular carcinoma” they proposed as a synonym), necrosis with 
formation of “peritheliomatous” areas, small round hyperchromatic nuclei, and 
mitotic activity. Following these descriptions, there is little uniformity in the 
criteria used by the various authors for inclusion of a given tumor into the 
poorly differentiated category. Indeed, some pathologists define these tumors 
on the basis of growth pattern  (trabecular, insular, solid) (Sakamoto et al 1983, 
Carcangiu et al. 1984, Papotti M et al 1993, Pellegritti  et al. 2002, Volante et al. 
2004, Pulcrano et al 2007, Ruffini et al. 2007), others suggest the use of high-
grade histology (mitotic counts and necrosis), rather than a specific growth 
pattern (Hiltzik et al. 2006) whereas still others attempted to combine both 
approaches (Volante et al. 2007).  
 
 
1.2 Prognostic Indicators  
 
Various prognostic factors have been identified and used to create the staging 
classification for well differentiated thyroid carcinoma but their value has not 
yet been validated for PDFC. Indeed,  there is neither a clear identification nor 
an established definition of prognostic factors in PDFC.  
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1.2.1 The TNM staging system (established by the International Union Against 
Cancer)  
 
The TNM staging system was introduced in 1987 and reviewed in 1992, 1997 
and 2002 (Hermanek et al. 1992, American Joint Committee on Cancer 2002). 
Since 1988, it has been recognized as the international reference staging 
system. The pathological classification (pTNM), is based on intra-operative 
and surgical-pathology data. It takes into account the patient’s age at diagnosis 
and three variables which are the extent of the primary tumor (T), the presence 
(N1) or absence (N0) of lymph-node metastases and the presence (M1) or 
absence (M0) of distant metastases. Tumor features taken into account are size 
and extension beyond the thyroid capsule. Table 2 present the criteria used in 
the 1992 and in the 2002 classifications.  
 
Table 2: The Tumor, Node, Metastases (TNM) scoring system (Hermanek et al. 
1992, American Joint Committee on Cancer 2002) 
 
1992 2002 
                                              Primary Tumor (T): 
T0: No evidence of primary tumor No evidence of primary tumor   
T1: Tumor ≤1cm limited to the thyroid Tumor ≤2cm limited to the thyroid 
T2: Tumor>1-≤4cm limited to the thyroid Tumor>2-≤4cm limited to the thyroid 
T3: Tumor>4cm limited to the thyroid Tumor>4cm limited to the thyroid or any 
Tumor with minimal extrathyroid extension 
T4: Any size extending beyond the thyroid 
Capsule. 
T4a: Tumor of any size with extension beyond the  
thyroid capsule and invades any of the following:  
subcutaneous soft tissues,larynx, trachea, oesophagus, 
recurrent laryngeal nerve. 
  T4b: Tumor invades prevertebral fascia, mediastinal 
vessels, or encases carotid artery 
Regional Lymph Node (N): 
 
N0 No regional lymph node metastasis No regional lymph node metastasis 
N1 Regional Lymph Node metastasis Regional Lymph Node metastasis 
 N1a: Metastases in pretracheal and paratracheal,  
including prelaryngeal and delphian lymph nodes 
 N1b: Metastases in other unilateral, bilateral or  
contralateral cervical or upper mediastinal lymph nodes
Distant metastasis (M): 
M0 No distant metastasis    No distant metastasis    
M1 Distant metastasis   Distant metastasis   
 
The 1992 (and 2002) classification system defines 4 stages with increasing risks of 
cancer-related death (Table 3). A comparison of different staging systems evidenced 
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that no other systems had statistically significant superiority over the 1992 TNM 
classification (Hermanek et al. 1992).  
The 2002 TNM classification is more complicated, and the definition of minimal or 
more extensive thyroid tumor extension may be difficult to define retrospectively 
(Loh 1997).. Six lymph nodes need to be examined at histology to qualify for the 
definition of N0 and the prognostic difference between level VI lymph-node 
metastases and other regional metastases has yet  to be validated.  
However, the prognostic value of the pathological classification (pTNM) was 
established with studies performed on patients with well-differentiated thyroid 
carcinoma and has not yet been validated for PDFC (American Joint 
Committee on Cancer 2002). 
 
Table 3: TNM Staging (Hermanek et al. 1992, American Joint Committee on 
Cancer 2002) 
 
1992 2002 
Age <45 years 
Stage I Any T, any N, M0  Any T, any N, M0   
Stage II Any T, any N, M1  Any T, any N, M1 
Stage III None None 
Stage IV None None 
Age >45 years 
Stage I T1, N0, M0  T1, N0, M0  
Stage II T2-T3, N0, M0 T2, N0, M0 
Stage III T4,N0,M0 or any 
T,N1,M0 
T3, N0, M0 or any  
T1-3, N1a, M0 
Stage IV Any T, any N, M1 None 
Stage IVA: T1-3, N1b, M0 or  
T4a, Any N, M0 
Stage IVB: T4b, Any N, M0 
 
Stage IVC: Any T, Any N, M1 
 
 
1.2.2 Oncological markers 
 
Recent studies in a number of other human malignancies indicate that the 
expression of certain cell cycle regulators has a prognostic utility (Takano et al.  
2000, Del Pizzo et al. 1999).  Indeed, in the papillary thyroid carcinoma, the 
expression of some subtypes of cyclins is correlated with clinical/histological 
stage at diagnosis and with clinical outcome. Moreover, the expression of 
thyroid functional genes is increased or decreased in well differentiated thyroid 
carcinoma. (Pickett et al. 2005, Ito Y et al. 2002), while their role in the PDFC 
is still unknown.  
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1.2.2.1 Ki-67 
 
Ki-67 is a nuclear antigen present in all proliferating cells; it is present in the 
G1, S, G2 and M phases of the cell cycle but absent in G0 cells. It is expressed 
in dividing tumor cells from patients with aggressive thyroid tumors to a larger 
extent than in benign adenomas and well differentiated carcinomas (Krohmn 
2003). Therefore, by staining for this antigen, it is possible to measure the 
tumor growth fraction directly and in a simple way. Ki-67 staining also yields 
results that are more reproducible than those obtained by counting mitotic 
figures.  
 
1.2.2.2 TPO, Galectin 3 and Dual Oxidase 
 
Galectin-3 occurs both in the nucleus and cytoplasm of many cells and on the 
cell surface. The multiple locations of this galectin-3 have suggested that it may 
have multiple functions. For example, galectin-3 is located in the nucleus of 
some cells and may be functionally important in RNA synthesis by being a 
component of the splicing complex with pre-mRNA. Galectin-3 can also bind 
cytokeratin, a cytoskeletal protein.  
Increased expression of galectins (especially galectin-3) has also been 
associated with tumor progression. The molecular significance of this 
relationship is proposed to be the interactions of galectins with 
polylactosamines on matrix proteins such as laminin, aiding cellular invasion. 
Since polylactosamines are also expressed on cancer mucins and enriched on 
the β1 6-branched glycans of tumor N-glycans, this molecular interaction 
could mediate homotypic adhesion of carcinoma cells as well. Galectin 
recognition may also explain how adding cell surface galactose to tumor 
mutants lacking the Golgi UDP-Gal transporter enhances metastasis (Cornil et 
al. 1990, Lotan et al. 1991, Inohara et al. 1996). 
Thyroperoxidase (TPO) is the key enzyme in the synthesis of thyroid 
hormones and is involved in two important reactions in the biosynthesis of 
thyroid hormone: the iodination of tyrosine residues on Tg and the 
intramolecular coupling reaction of iodinated tyrosines (figure 1). 
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A number of studies have been published demonstrating the value of a 
monoclonal antibody directed against TPO (monoclonal antibody 47) in the 
diagnosis of thyroid lesions, and although the specificities have ranged from 
68% to 90%, the sensitivities have consistently been excellent, between 97% 
and 100%. (Weber et al. 2004, De Micco et al. 1994) 
  Immunohistochemistry with antibodies directed against TPO (monoclonal 
antibody 47) and Galectin-3 has been used to differentiate benign from 
malignant follicular tumors : typical cases are usually distinguished but in 
doubtful cases these antibodies are not reliable enough to be used in clinical 
practice (Weber et al. 2004). Galectin 3 is a positive marker of malignancy 
(expressed in cancer but not in benign lesions or normal tissue), while TPO is a 
negative marker (expressed in normal tissue and in benign lesions, but not in 
cancer). 
In a retrospective study galectin-3 and TPO showed diagnostic and prognostic 
value for patients with papillary carcinoma (Weber et al. 2004) while their role 
in the PDFC carcinoma is still unknown.  
Dual oxidase (Duox) is a glycoflavoprotein involved in thyroid hormone 
biosynthesis as the thyroid H2O2 generator (figure 1) (Caillou et al. 2001). 
I-
TPO
T4
Tg
MIT
DIT
T3
DUOX
NADP+ NADPH
O2
H2O2
Tyr
Tg
Tyr
Tyr
Tyr
Tireoglobulin
Apical membrane 
Cytoplasme
Colloid
 
Fig. 1: Role of TPO and Dual oxidase in thyroid hormone synthesis. 
The iodination of tyrosine residues on thyroglobulin and the intramolecular 
coupling reaction of iodinated tyrosines are catalyzed by thyroperoxidase 
(TPO) under oxidative conditions for which H2O2 is required. H2O2 
production is catalyzed by an H2O2-generating system, for which DUOX 
is essential component. 
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Duox expression is found in well differentiated thyroid carcinomas able to pick 
up radioiodine and with detectable expression of TPO, pendrin and sodium 
iodide symporter (Lacroix et al. 2001) but its expression has not been evaluated 
in PDFC 
 
1.2.2.3 P53 
 
Activation of p53 may lead to growth arrest at both G1 and G2 phases of the 
cell cycle. Arrest in G1 prevents replication of damaged DNA, while arrest in 
G2 prevents improper segregation of chromosomes. p53 may also arrest DNA 
replication in S phase, which is usually masked by the prior G1 arrest. The 
p53-target gene, p21 (waf-1/cip-1), is the key player in G1 arrest. p21 inhibits 
different complexes of cyclin/cyclin-dependent kinases (cdks) (Cyclin D-
Cdk4/6 and Cyclin A, E-Cdk2) that sequentially phosphorylate the 
retinoblastoma (pRb) protein, and as a result release the S phase-promoting 
E2F-1 transcription factor (figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2:  Action of p53.  
Activation of p53 may lead to growth arrest at both G1 and G2 phases of the 
cell cycle. The activation of p21 is central for mediating G1 arrest by 
inhibition of multiple cyclin/cyclin-dependent kinases (CDK complexes). As 
a result, retinoblastoma protein (Rb) is not phosphorylated, and it inactivates 
E2F-1transcription factor through recruitment of histone deacetylase 
(fig.1A). p53 triggers several parallel pathways that block the formation of 
the mitotic cyclin B/Cdc2 complex and inhibit its activity. This activity of 
p53 is essential for maintaining the G2 arrest. (fig.B) Defects in one of these 
pathways cause premature entry into M phase (adapted from Sionov et al. 
2002) 
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The ability of p53 to arrest cells at multiple checkpoints is crucial for 
suppression of amplification of genetic alterations which otherwise can lead to 
cancer. Inactivation of p53 results in a loss of the DNA damage-induced G1/S 
checkpoint, impaired G2 arrest, and the appearance of aneuploid and polyploid 
cells.  
In the thyroid tumors, point mutations of p53 occur in more than half of 
anaplastic carcinomas and in a significant proportion of poorly differentiated 
carcinoma but not in well-differentiated tumors, either benign or malignant. 
These data indicate that p53 inactivation is likely to play a direct role in 
triggering tumor dedifferentiation and progression to poorly differentiated and 
anaplastic carcinoma. Indeed p53 may serve as a prognostic factor in the 
poorly differentiated carcinoma (Nikiforov 2004) 
 
1.2.2.4 Cyclins 
 
Cyclins represent a heterogeneous group of proteins that are responsible for the 
regulation of the cell cycle (figure 3). Cyclin A, cyclin B and cdc2 are the G2-
M regulators of the cell cycle and their expression was investigated in a variety 
of human tumors (Del Pizzo et al. 1999, Takano et al. 2000) but their relevance 
in differentiated thyroid tumors is unknown. A recent study investigated the 
expression of these 3 proteins in anaplastic thyroid carcinomas: cyclin A was 
overexpressed in all cases while cyclin B was overexpressed in only 19% of 
these tumors. These results suggest that cyclin A contributes to the aggressive 
character of thyroid carcinoma (Pickett et al. 2005, Ito et al. 2002). 
Cyclin D1 and E2F-1 are essential for the regulation of the G1/S transition 
through the cell cycle. Over-expression of cyclin-D1 was found in the majority 
of the benign and malignant thyroid tumors (Lazzereschi et al. 1998), 
compared with normal thyroid tissue. Because cyclin D1 normally activates 
E2F-1, up-regulation of cyclin D1 may lead to E2F-1 overexpression in thyroid 
lesions (Saiz et al. 2002). In particular, papillary carcinomas showed the 
highest expression for cyclin-D1 (Basolo et al. 2000, Khoo et al 2002) and low 
expression of Cyclin-E, associated to poor prognosis while the expression of 
these cyclins in the follicular carcinoma  has not been studied.  
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1.2.2.5 Vascular endothelial growth factor (VEGF) and Epidermal growth 
factor receptor (EGF-R) 
 
Angiogenesis, the formation of new blood vessels, plays an integral part in the 
pathogenesis and spread of differentiated thyroid cancer (Soh et al. 1997). FTC 
is the most angiogenesis-dependent tumor of the thyroid. One of the major pro-
angiogenic factors in thyroid tumors is vascular endothelial growth factor 
(VEGF) (figure 4) and the inhibition of VEGF production or VEGFR 
phosphorylation has been shown to reduce the growth of FTC xenografts 
(Younes et al. 2005 ). 
 
 
 
 
 
 
Fig. 3: A current view of the variations in cyclin–CDK activities 
throughout the cell cycle of a mammalian cell.  
In animal cells, progression through the G1 restriction point is controlled by 
complexes of Cdk2, Cdk4 and Cdk6 with D-type cyclins. Cdk2/cyclin E 
complexes function later in G1 and are required for the G1 to S transition. 
Cdk2/cyclin A complexes are then required for progression through S phase, 
and Cdc2/cyclin B complexes drive the G2 to M transition (adapted from Lodish 
et al. 1995). 
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Epidermal growth factor receptor (EGFR) is a trans-membrane cell-surface 
glycoprotein that stimulates cellular growth and angiogenesis (figure 5).  In 
follicular cell EGFR overexpression increases cellular proliferation and 
enhances thyroid cancer invasiveness (Carpenter and Cohen 1990, Ullrich and 
Schlessinger 1990, Aaronson 1991). 
 
 
 
Fig. 4: Major signal transduction pathways induced by 
VEGF.  
In endothelial cells, VEGF signaling through activated VEGFR-2 
involves the MAP-kinase pathway (MEK-ERK) as well as the PI3 
kinase-AKT pathway. In endothelial cells, activation of the MAP-
kinase pathway mediates cell proliferation, while signaling 
through the PI3 kinase-AKT pathway leads to cell survival. 
Recruitment of phospholipase C γ (PLC-γ) followed by activation 
of protein kinase C (PKC) and endothelial nitric oxide synthetase 
(eNOS), finally, is involved in induction of vascular permeability. 
(Adapted from Clauss 2000) 
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An increased expression of EGFR has been found in papillary and 
undifferentiated thyroid carcinomas (Hoelting et al.1994, Aasland et al. 1990, 
Schiff et al. 2004, van der Laan et al. 1995, Westermark et al. 1996, Akslen et 
al. 1993) and seems to be related to the dedifferentiation of the tumor (ref: 
Schiff et al. 2004). Moreover, the coexpression of EGF and EGFR is associated 
with bone metastases of follicular thyroid carcinoma and the blockade of 
EGFR signaling decreases the growth and invasion of FTC cells in vitro 
(Hoelting et al. 1995): However its role has not yet been demonstrated in 
PDFC. 
 
 
 
Fig. 5: EGFR signal trasduction.  
Ligand binding with EGFR results in receptor homo- or heterodimerization 
at the cell surface (i.e. either with another EGFR or with another member 
of the erbB family, respectively), followed by internalization of the 
dimerized receptor. After dimerization, autophosphorylation of the 
intracytoplasmic EGFR tyrosine kinase domains occurs. Phosphorylated 
tyrosine kinase residues serve as binding sites for the recruitment of 
signaling molecules, such as Ras. These signaling molecules have the 
ability to phosphorylate other “downstream” molecules, leading to a chain 
of chemical reactions ultimately leading to the cell nucleus which 
ultimately leads to gene activation (Adapted from Salomon et al.  1995). 
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2. AIM OF THE STUDY  
 
PDFC are a heterogeneous group of tumors which show peculiar histological 
and clinical features with more aggressive behavior than WDTC.  
PDFC are a heterogeneous group of tumors which show peculiar histological 
and clinical features with more aggressive behavior than WDTC. The definition 
of  histology, epidemiology, clinical presentation and natural history of PDFC 
represents the key point to understand the molecular bases of these tumors and, by 
a clinical point of view, to recognize, treat and manage these tumors. 
 
Therefore, the main objectives of my doctorate thesis were: 
 
• To analyze initial presentation, treatment, outcome and prognostic 
factors according to the TNM classification in patients with PDFC, 
identified on the basis of a trabecular, insular, or solid (TIS) growth 
pattern.  
 
• To define the histological characteristics of PDFC, searching for 
relationships between the clinical presentation, outcome and 
histological features of this thyroid tumor. 
 
 
• To evaluate the expression of markers of proliferation and of 
differentiation by immunohistochemistry. 
 
• To identify prognostic factors of PDFC correlating  the histological 
architecture, cytological characteristics, the expression of markers of 
proliferation and of differentiation with survival and clinical outcome.  
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3.  MATERIALS AND METHODS 
 
3.1 Clinical Study 
 
3.1.1 Patients  
 
Clinical charts were retrieved from the archives, in according to a list obtained 
from the central computer system of Institut Gustave Roussy  (IGR) of cases 
treated from the start of their illness at Institut Gustave Roussy, Villejuif, 
between 1975 and 2000. This search  was conducted using the terms “thyroid”, 
“carcinoma” and  “follicular carcinomas”. The patients affected by papillary, 
medullary, well differentiated follicular or undifferentiated carcinoma were not 
included in the study. 
In all, 40 patients with PD carcinomas were selected from series of 200 patients 
with follicular thyroid carcinoma. For the 200 patients, all histologic 
hematoxylin and eosin-stained slides were reviewed by a single pathologist (Dr 
B. Caillou) who was unaware of clinical data, for confirmation of the 
diagnosis. The follicular cell origin of the tumors is immunohistochemically 
confirmed with positive thyroglobulin immunoreactivity and no stain for 
calcitonin.  
Inclusion criteria were the presence of either focal, extensive or predominant 
TIS growth patterns in follicular thyroid carcinomas. Oxyphilic (Hürthle cell) 
tumors, that differed from classical follicular carcinomas for their 
mitochondrion-rich cytoplasm, were included in this study.  
For all 40 patients, information regarding gender, age, tumor size and stage, 
therapy administered and outcomes were collected. 
Stage for follicular FTC was assigned using the TNM system of American Joint 
Committee on Cancer (tab.2-3)American Joint Committee on Cancer 2002, 
Hermanek and Sobin 1992). Follow up data regarding recurrences and survival 
were obtained from the clinical chart of IGR. Tumor progression and/or disease 
recurrence was established on the basis of clinical examination and new 
findings on radiological and nuclear scanning. Dates of disease recurrence, 
newly found metastases and death were recorded. The end point was June 
2005, or the date of death or loss to follow-up. 
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3.2 Histological Study 
 
Four to 15 hematoxylin and eosin-stained slides were available from each 
patient. Histopatologic review was conducted by a pathologist, who was 
unaware of clinical characteristics or outcome of patients. On review, the 
following pathologic parameters were evaluated and recorded:  
 
1. Tumoral architecture, defined as the presence of a trabecular 
pattern  and/or insular and/or solid and/or polymorph pattern 
2.  Presence of  Hürthle cell features, defined as the presence in the 
majority (>75%) of tumor cells of eosinophilic, granular cytoplasm 
3. Presence and grade of atypical nuclear pattern: we used a score 
between 1 and 3 (1: <1% positive cells, 2: between 1-5% positive 
cells, 3: between 6-10% positive cells) 
 
 
3.3 Immunohistochemistry  
 
3.3.1 Methods  
 
All slides were deparaffinized in xylene and rehydrated in a graded series of 
ethanol. To retrieve the antigenicity, the sections were then placed in a 
preheated 10mM citrate buffer (pH 6.0) and heated in various conditions. The 
sections were then immersed in methanol containing 0.3% hydrogen 
peroxidase for 5 min to block the endogenous peroxidase activity and were 
incubated during 30 min with 2.5-5 % blocking horse serum to reduce 
nonspecific binding. Sections were incubated with primary antibody according 
to previously validated conditions. Following several washes with PBS 
(phosphate-buffered saline), the slides were reacted for 30 min with an 
universal secondary biotinylated antibody, then with avidin-biotinylated 
horseradish peroxidase H complex (ABC kit, Vector Laboratories, Burlingame, 
CA). Diaminobenzidine was used as a chromogen (8 min), and commercial 
haematoxylin was used for counterstaining. For positive controls for each 
antibody, sections of thyroid previously validated by us to be strongly positive 
were used; to obtain a negative control for each antibody, incubation was 
performed without the primary antibody. Indeed, the expression of these 
markers in the tumor and in the normal thyroid tissue was compared in the 33 
samples for which non tumoral tissue was available.  
Specific antibodies used in the study were as follows: anti-cyclin A, anti-cyclin 
B, anti-cyclin E (1/25 dilution; monoclonal antibody; Novocastra, Newcastle 
upon Tyne, UK), anti-cyclin D1 (1/100 dilution; monoclonal antibody; 
Neomarkers, Fremont, USA), anti-Ki67 (1/25 dilution; monoclonal antibody; 
Dako, Glostrup, Denmark), anti-TPO (1/4 dilution; monoclonal antibody; 
BioCytex, Marseille, France), anti-galectin-3 (1/25 dilution; monoclonal 
antibody; Novocastra, Newcastle upon Tyne, UK) anti-Tg (1/100 dilution; 
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monoclonal antibody; Dako, Glostrup, Denmark), anti-VEGF (1/50 dilution; 
polyclonal antibody; SantaCruz, Heidelberg, Germany), anti-p53 (1/25 
dilution; monoclonal antibody; Dako, Glostrup, Denmark), anti-Duox (1/25 
dilution; polyclonal antibody raised at IGR (21)), anti-EGFR (monoclonal 
antibody; Ventana, Illkirch Cedex, France) antiserum.  
 
 
3.3.2 Immunohistochemical analysis  
 
Analysis of stained sections was performed with Dr Caillou at Institut Gustave 
Roussy- department of Pathology,. For each patient, all spots were analyzed 
and representative zones were chosen to count 500 cells. For each marker, the 
parameters evaluated were: 
 
1. localization of the marker: in the nucleus, cytoplasm and membrane 
2. number of positive cells: we used a score between 1 and 4 (1: <1% 
positive cells, 2: between 1-5% positive cells, 3: between 6-10% 
positive cells and 4: >10% positive cells) 
3. intensity of expression: we used a score between 1 and 3  (1: low, 2: 
moderate, 3: high)  
 
 
3.4 Statistical Analysis 
 
The following clinical criteria were recorded for all patients: gender, age at 
diagnosis, TNM stage (American Joint Committee on Cancer 2002), 
histological characteristics of the thyroid tumor (microfollicular, trabecular, 
insular, solid, polymorph, Hürthle cells), and nuclear atypia. For tumor 
markers, we recorded staining location, number of positive cells and staining 
intensity, as described above.  
Overall survival and metastases free survival were studied according to these 
parameters by using univariate and multivariate analysis. Multivariate analysis 
included variables for which p-value was less than 0.1 in the univariate 
analysis. For all analyses, two sided tests were employed and the 0.05 level of 
significance was used. Survival rates and their 95% confidence intervals were 
estimated by the Kaplan-Meier method (Kaplan and Meier 1958). The log-rank 
test ( Peto et al. 1977) was used to compare overall and metastasis free survival 
rates (univariate analysis). The relative risk of death and of occurrence of 
metastases according to each variable were estimated using Cox’s proportional 
hazards regression model ( Cox 1972).  
The analysis was performed using SAS® software (version 9.1, SAS Institut, 
Cary, NC, USA). 
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4. RESULTS 
 
4.1 Patients 
 
Forty patients with poorly differentiated follicular carcinomas (PDFC) were 
included in the analysis; there were 22 females and 18 males, with a mean age 
at diagnosis of 46.7 years [16-81 yrs]. No patient had a history of thyroid 
carcinoma in the family or of radiation exposure. The mean tumor size was 3.9 
cm [0.5-12 cm]. Twenty patients were classified as T0,T1, or T2, 19 as T3 or 
T4 and one patient as Tx. Lymph-node metastases were present in 16 patients 
(Table 4). Nine patients had distant metastases at discovery of the disease, in 
lungs (5 patients), bones (1 patient) and in both lungs and bones (3 patients).  
Median follow-up was 3.9 years [0-19.7 yrs], during which 9 patients 
developed distant metastases: in lungs (2 patients), bones (2 patients), in both 
lungs and bones (4 patients) and lungs, bones and brain (1 patient).  
Radioiodine uptake was present in metastases on radioiodine (131I) whole 
body scan performed 3 to 5 days after the administration of 3.7GBq in 6 and 
absent in 9 of the 15 patients with distant metastases who were treated with 
radioiodine; the other 3 patients did not receive any radioiodine treatment for 
poor clinical condition and the presence of uptake could not be determined. 
When present, radioiodine uptake in the metastases was low, and no 
significant clinical benefits were observed after treatment with radioiodine. 
Twelve patients, all with distant metastases died after a mean follow-up of 2.6 
years [0.02-6.5 yrs] after initial treatment. 
 
Table 4: Clinical  characteristics in 40 patients with PDFC treated and 
followed-up at  IGR 
 
Clinical characteristics 
Age   
≤ 45 18 
> 45 22 
Gender  
M 18 
F 22 
T (TNM)*  
Stages 0,1,2 20 
Stages 3,4 19 
Lymph Nodes (TNM)**  
Absent 20 
Present 16 
 
* One missing value for tumor size. 
** One missing value for lymph nodes metastases. 
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4.2 Histological  Characteristics 
 
All patients had clear-cut signs of malignancy with different amounts of 
atypical nuclear pattern, mitosis and of necrosis. The characteristic histological 
architecture (TIS) represented the vast majority of the tumor areas in all tumor 
samples (figure 6) with the presence of trabeculae  in 31 patients (77%), 
closely intermingled  with  insular architecture in 8 patients (20%) and solid 
architecture in 3 patients (8%). Microfollicles were found in variable amounts 
in 27 patients (67%). Polymorph architecture with a clearly separate 
distribution of various architectures was found in 14 patients (35%) and  
Hürthle cells were observed in 13 patients (33%) (Table 5).  
 
 
 
 
 
Among the 18 patients with distant metastases, predominant trabecular 
architecture was found in 16 (89%). Insular pattern was found in 3 patients 
(17%), in association with a trabecular pattern in 1 and with a solid pattern in 2 
(11%); microfollicles were observed in 12 patients (67%) and Hürthle cells in 6 
 
Fig. 6. Histological aspects of poorly differentiated follicular thyroid cancer 
(hematoxylin and eosin stain; original magnification: _100).  
(A) Poorly differentiated trabecular carcinoma: dense proliferation of tumor cells 
without papillary or follicular structures. Note the absence of colloid formation 
and the presence of a trabecular pattern (arrows).  
(B) Poorly differentiated insular carcinoma: presence of ‘‘islands’’ of tumor cells 
with well-defined limits and with ‘‘holes’’ filled up with colloid (arrows).  
(C) Poorly differentiated solid carcinoma: diffuse solid pattern of tumor cells 
without any architecture. (D) Poorly differentiated microfollicular 
carcinoma:multiple microfollicles are seen.
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(33%). Similar features were observed in patients without metastases. The 
polymorph architecture was found in 3 patients with metastases, less frequently 
than in 11 of the 22 patients without metastases (Table 5). 
  
 
Table 5: Histological characteristics in 40 patients with PDFC treated and 
followed-up at  IGR 
 
 
Histological 
Characteristics 
Metastasis absent Metastasis present 
Microfollicular   
Yes  15 12 
No 7 6 
Trabecular   
Yes 15 16 
No 7 2 
Insular   
Yes 5 3 
No 17 15 
Solid   
Yes 1 2 
No 21 16 
Polymorph    
Yes 11 3 
No 11 15 
Hurthle*   
Yes 7 6 
No 14 12 
 
* One missing value for the histological classification into Hurthle cells. 
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4.3 Immunohistochemical study 
 
 
Twenty nine (72%) PDFC were positive for Cyclin A and 31 (77%) for Cyclin 
B1. A nuclear expression of Cyclin E was found in 31 PDFC (77%) 
(figure7A), whereas no expression of Cyclin D1 was found (figure 7B). Ki-67 
staining was positive in 28 PDFC (72%) (figure 7C) with a percentage of 
positive cells of 1-5% in 10 tumors, of 6-10% in 6, and > 10% in 12. P53 
staining was positive in 20 PDFC (50%).  
Galectin 3 staining was positive in 21 PDFC (52%). Duox staining was 
positive in 17 PDFC (43%) and TPO in 26 (65%), and there was no clear 
relationship between staining for Duox and for TPO (both stainings being 
positive in 12 tumors, negative in 9, and either one positive in 19 tumors). In 
tumor positive for TPO, staining was located in the cytoplasm and not in the 
membrane (figure 7D). EGFR was positive in 29 PDC (72%) and VEGF in 38 
(95%). 
 
 
 
 
4.4 Prognostic Factors For The Occurrence Of Metastases And Thyroid 
Cancer Mortality 
4.4.1 Occurrence of distant metastases  
 
Distant metastases occurred in 4 of the 18 patients aged less than 45 years and 
in 14 of the 22 patients older than 45 years. Mean age at the first treatment was 
58.7 years [32-81 yrs] in the 18 patients who developed metastases and 36.9 
years [16-63 yrs] in the other 22 patients (p < 0.0001) (Table 6). 
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Fig.7 Immunohistochemical studies in poorly differentiated thyroid 
cancer 
 
(A) Strong nuclear CyclinE-positive stanining in all tumor cells  
(B) CyclinA negative staining in all tumor cells  
(C) Ki-67 positive staining in the majority tumor cells 
(D) TPO-positive staining in the cytoplasm in all tumor cells  
A B
DC 
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Table 6: Clinical and histological factors of metastases occurrence in 40 patients 
with PDFC treated and followed-up at  IGR  -  Univariate analysis 
 
Clinical characteristics                     Metastases           RR    95% CI           P 
Age       
≤ 45  04/18    
> 45  14/22 1.08 1.04-1.12 < 0.0001 
Gender      
M  07/18    
F  11/22 1.47 0.57-3.8 0.42 
T (TNM)*      
Stages 0,1,2  03/20    
Stages 3,4  14/19 3.50 1.84-6.64 0.0001 
Lymph Nodes (TNM)**     
Absent  05/20    
Present  09/16 2.50 0.84-7.55 0.1 
Histological Characteristics    
Microfollicular     
Yes   12/27    
No  06/13 0.91 0.34-2.45 0.86 
Trabecular      
Yes  16/31    
No  02/09 2.50 0.57-10.9 0.22 
Insular      
Yes  03/08    
No  15/32 0.72 0.21-2.50 0.6 
Solid      
Yes  02/03    
No  16/37 1.69 0.38-7.4 0.48 
Polymorph       
Yes  03/14    
No  15/26 0.26 0.07-0.93 0.04 
Hurthle***      
Yes  06/13    
No  12//26 1.04 0.38-2.84 0.94 
Nuclear Atypia     
Yes  09/24    
No  09/16 1.0 0.48-2.08 0.99 
 
* One missing value for tumor size. 
** One missing value for lymph nodes metastases. 
*** One missing value for the histological classification into Hurthle cells.
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Patients younger than 45 years had metastasis free survival significantly longer 
than patients older than 45 years (p = 0.002) (figure 8). 
 
 
 
 
 
 
Among the 18 patients with metastases, 14 had a primary tumor larger than 4 
cm and/or with an extension beyond the thyroid capsule, 3 had a primary tumor 
smaller than 4 cm and one was staged as Tx. Nine patients with distant 
metastases had lymph-node metastases at the time of diagnosis (Table 6). 
The analyses of histological factors showed that only polymorph pattern was 
associated with a lower risk of metastases (RR : 0.26 ; 95% CI  [0.07-0.93] ; 
p=0.04) (Table 6).
.  
Fig. 8: Metastases free survival according to age at the time of 
diagnosis. 
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Univariate and multivariate analysis showed that an older age at the time of 
initial treatment and a larger extent of the primary tumor were significantly 
associated with an increased risk of metastases (Tables 1-4). Indeed, the RR of 
metastases was 1.08 in patients older than 45 years, [95% CI:1.02-1.14; 
p=0.003] and  was 3.24, [95% CI:1.56-6.72; p=0.001] in patients classified as 
T3 and T4, as compared to patients classified as T0, T1 or T2 (Table 7).  
Instead, a polymorph pattern was associated with a lower risk of metastases 
[RR : 0.26; 95% CI:0.07-0.93; p=0.04] (Table 7).  
 
Table 7: Clinical and histological factors of metastases occurring and 
death in patients treated and followed-up at  IGR  - Multivariate analysis 
 
Clinical characteristics                    Metastases RR 95% CI p 
Age       
≤ 45  04/18    
> 45  14/22 1.08 1.04-1.12 0.003 
T (TNM)*      
0,1,2  03/20    
3,4  14/19 3.24 1.56-6.72 0.001 
Histological Characteristics    
Polymorph       
Yes  03/14    
No 
  
15/26 
 
0.26 
 
0.07-0.93 
 
0.04 
 
 
With reference to immunohistochemical factors, Cyclin A was more frequently 
expressed in patients with metastases, (p=0.1 at univariate analysis) (Table 8) 
whereas TPO expression was linked to a lower risk of metastases [RR : 0.74 
95% CI:0.57-0.97; p=0.03] (Tables 5-11). The expression of the other markers 
studied was not different between patients with and without distant metastases. 
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Table 8 : Immunohistochimical factors of metastases occurrence in 40 
patients with PDFC - Univariate analysis 
 
 
RR 
(for  
metastases)   95% CI p 
Cyclin A    
Cells with nuclear marking     
Per degree of positive cells  
Percentage 1.37 0.92-2.04 0.1 
Cyclin B1    
Cells with cytoplasmic expression    
Per degree of positive cells  
Percentage 1.26 0.88-1.79 0.21 
Cycline E    
Cells with nuclear expression    
Per degree of positive cells  
Percentage                          0.91 0.67-1.22 0.53 
Ki67    
Cells expression    
Per degree of positive cells  
Percentage 1.14 0.84-1.54 0.39 
TPO    
Cells with cytoplasmic expression    
Per degree of positive cells  
Percentage 0.74 0.57-0.97 0.03 
Galectine 3    
Cells with cytoplasmic expression    
Per degree of positive cells  
Percentage 1.01 0.78-1.29 0.93 
Galectine 3    
Cells with nuclear expression    
Per degree of positive cells  
Percentage 0.95 0.74-1.22 0.69 
VEGF    
Cells with cytoplasmic expression    
Per degree of positive cells  
Percentage 0.91 0.53-1.54 0.71 
EGFR    
Cells with membrane expression    
Per degree of positive cells  
Percentage 0.86 0.67-1.13 0.28 
Duox    
Per degree of positive cells  
Percentage                       0.71 0.44-1.16 0.18 
P53    
Cells with nuclear expression    
Per degree of positive cells  
Percentage 0.9 0.71-1.15 0.4 
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4.4.2 Survival  
 
At 5 years, the overall survival rate was 63% and the metastases-free survival 
rate was 57% (figure 9).  
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Fig. 9: Overall and metastases free survival in the whole series  
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Survival of patients without metastases was indeed significantly longer than for 
patients with metastases (p <0.001) (figure 10). 
 
 
 
Univariate and multivariate analysis showed that an older age at the time of 
initial treatment and a larger extent of the primary tumor were associated with 
a higher risk of death (Tables 9-10). Indeed, the RR of death was 1.08 [95% 
CI:1.03-1.14; p=0.002] in patients older than 45 years and 3.14 [95% CI:1.02-
9.7; p=0.04]  in patients classified as T3 and T4 as compared to patients 
classified as T0, T1 or T2 (Table 10). No association was found between 
histological variables and survival (Table 9) 
 
 
 
Fig. 10:  Survival according to metastases occur (n= 40). 
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Table 9: Clinical and histological factors of death in 40 patients with 
PDFC treated and followed-up at  IGR  -  Univariate analysis 
 
* One missing value for tumor size. 
** One missing value for lymph nodes metastases. 
*** One missing value for the histological classification into Hurthle cells 
 
Clinical characteristics  Deaths   RR 95% CI p 
Age      
≤ 45 0/18    
> 45 12/22 1.12 1.06-1.17 < 0.0001 
Gender     
M 4/18    
F 8/22 1.76 0.53-5.87 0.36 
T (TNM)*     
Stages 0,1,2 1/20    
Stages 3,4 10/19 4.36 1.80-10.6 0.001 
Lymph Nodes (TNM)**     
Absent 3/20    
Present 6/16 2.28 0.57-9.20 0.29 
Histological Characteristics     
Microfollicular     
Yes  8/27    
No 4/13 0.86 0.26-2.86 0.8 
Trabecular     
Yes 10/31    
No 2/9 1.5 0.33-6.87 0.6 
Insular     
Yes 3/8    
No 9/32 1.01 0.27-3.73 0.99 
Solid     
Yes 1/3    
No 11/37 1.23 0.16-9.57 0.85 
Polymorph      
Yes 3/14    
No 9/26 0.46 0.12-1.72 0.25 
Hurthle***     
Yes 4/13    
No 8/26 1.02 0.303.44 0.98 
Nuclear Atypia     
Yes 9/24    
No 9/16 1.63 0.68-3.90 0.27 
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Table 10: Clinical and histological factors of death in patients treated and 
followed-up at  IGR  - Multivariate analysis 
 
The analysis of immunohistochemical factors showed that a high expression of 
Duox was associated with a lower risk of death [RR : 0.14;  95% CI:0.02-0.97; 
p=0.04](Tables 11-12) whereas the expression of the other markers studied was 
not statistically significant (Table 12). 
 
Table 11: Immunohistochimical  factors of metastases occurring and death 
in patients treated and followed-up at  IGR   - Multivariate analysis 
 
 RR 95% CI p 
Metastases    
 
TPO 
   
Cells with cytoplasmic expression    
Per degree of positive cells percentage 0.74 0.57-0.97 0.03 
 
Deaths    
 
Duox 
   
Per degree of positive cells percentage        
                0.14 0.02-0.97 0.04 
A score  from 1 to 4 was used to quantify the number of positive cells : 1: < 1%  of 
positive cells ;   2: between 1 and 5%  of  positive cells ;  3:  between 6 and 10%  of  
positive cells  ;   4: >10%  of positive cells) 
Clinical 
characteristics               Deaths                      RR 95% CI p 
Age      
≤ 45     0/18    
> 45    12/22 1.08 1.03-1.14 0.002 
T (TNM)*     
0,1,2     01/20    
3,4    10/19 3.14 1.02-9.7 0.04 
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Table 12: Immunohistochimical factors of death in 40 patients with PDFC 
- Univariate analysis 
 
RR  
(for death)   95% CI   p 
Cyclin A    
Cells with nuclear marking     
Per degree of positive cells  
Percentage 1.23 0.78-1.95 0.36 
Cyclin B1    
Cells with cytoplasmic expression    
Per degree of positive cells  
Percentage 1.13 0.74-1.73 0.56 
Cycline E    
Cells with nuclear expression    
Per degree of positive cells  
percentage                          0.83 0.58-1.18 0.31 
Ki67    
Cells expression    
Per degree of positive cells  
Percentage 1.10 0.76-1.60 0.61 
TPO    
Cells with cytoplasmic expression    
Per degree of positive cells  
Percentage 0.79 0.58-1.07 0.13 
Galectine 3    
Cells with cytoplasmic expression    
Per degree of positive cells  
Percentage 0.96 0.71-1.31 0.80 
Galectine 3    
Cells with nuclear expression    
Per degree of positive cells  
Percentage 0.95 0.70-1.29 0.76 
VEGF    
Cells with cytoplasmic expression    
Per degree of positive cells  
Percentage 0.77 0.45-1.31 0.34 
EGFR    
Cells with membrane expression    
Per degree of positive cells  
Percentage 0.79 0.58-1.07 0.13 
Duox    
Per degree of positive cells  
percentage                       0.14 0.02-0.97 0.04 
P53    
Cells with nuclear expression    
Per degree of positive cells  
Percentage 0.86 0.62-1.16 0.32 
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5. DISCUSSION 
 
Poorly differentiated (PDFC) carcinomas of the thyroid represent an 
heterogeneous but distinct group of tumors, clinically and 
histopathogenetically intermediate between follicular-derived well-
differentiated and anaplastic carcinomas. However, the criteria for the 
diagnosis of PD tumor are far from being well established. Indeed, although the 
number of the article written on the subject of PD carcinoma has grown 
exponentially during the last decade, the criteria of inclusion used by the 
various authors are very different. Some pathologists selected these tumors on 
the basis of growth pattern  (trabecular, insular, solid) (Sakamoto et al 1983, 
Carcangiu et al. 1984, Papotti M et al 1993, Pellegritti  et al. 2002, Volante et al. 
2004, Pulcrano et al 2007, Ruffini et al. 2007), others used of high-grade 
histology (mitotic counts and necrosis) rather than a specific growth pattern 
(Hiltzik et al. 2006), whereas still others attempted to combine both approaches 
(Volante et al. 2007). Moreover, there are additional source of controversies on 
PD carcinomas. Some studies incorporated both follicular-derived tumors and 
papillary-derived tumors into PD carcinoma group (Nishida et al 1999, Papotti 
et al. 1993) whereas others classify the tumors with TIS growth pattern 
associated with characteristic nuclear features of papillary carcinoma as the 
solid variant of this tumor type (Nikiforov et al. 2001, Volante M et al. 2007). 
The objective of the current study was to define the histological characteristics 
of PDFC, searching for relationships between the clinical presentation, 
outcome and histological features of this thyroid tumor. We also wanted to 
identify prognostic factors of PDFC correlating  the histological architecture, 
cytological characteristics, the expression of markers of proliferation and of 
differentiation with survival and clinical outcome. Therefore, we identified 40 
patients affected by PDFC, defined exclusively on the basis of growth pattern 
and we evaluated the prognostic significance of various clinical, histological 
and immunohistochemical characteristics. The small number of patients is due 
to the scarcity of PDFC and to the fact that we evaluated only those patients 
who were initially treated at Institut Gustave Roussy, and finally to the 
exclusion of tumors with a papillary component. 
Our study confirms that PDFC had a clinical course intermediate between the 
indolent course observed in well differentiated thyroid carcinoma and the 
aggressive course of undifferentiated carcinoma (Sakamoto et al 1983, Volante et 
al. 2004, Hiltzik et al 2006, Pellegritti et al. 2002, Volante M and 2007). Indeed, 
at 5 years the overall survival rate was 63% and the metastasis free survival 
rate was 57%. In a recent retrospective study of PDC defined by the presence 
of mitosis and necrosis, the survival rate was similar (Hiltzik et al 2006). This 
similarity is probably due to the aggressive behavior of PDC, independently of 
whether they are defined on the basis of growth pattern and/or other criteria.  
We did not find any relationship between the presence of a particular 
histological subtype and metastasis free survival. Only, a polymorph 
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architecture was more frequently observed in patients without distant 
metastases in the univariate analysis, and this may be related to the presence of 
a more differentiated component in these tumors. As reported in literature 
(Volante et al. 2004), the presence of Hurthle cells was not associated with a 
more aggressive behavior. 
Our study confirms that prognostic factors identified for well differentiated 
thyroid cancers also apply to PDFC. An older age at the time of initial 
treatment was associated with a poor outcome (Volante et al. 2004, Baloch and 
LiVolsi 2001, d’Avanzo 2004, Papotti et Bussolati 1994), and in patients older 
than 45 years, metastases free survival and overall survival rates were lower 
(Fig.3). A larger tumor size (larger than 4 cm) and/or the invasion of the 
thyroid capsule was associated with a higher risk of distant metastases and with 
a poor survival (Hiltzik et al 2006, Baloch and LiVolsi 2001, d’Avanzo 2004, 
Papotti et Bussolati 1994). Finally, survival rate was lower among patients with 
distant metastases, and the 12 deaths were observed in the 18 patients who 
developed distant metastases.  
Concerning the immunohistochemical study, an absence of detectable TPO 
expression has been reported in differentiated and in undifferentiated thyroid 
carcinomas (Weber 2004, De Micco 1994, De Micco 1994). In the current 
study, detectable TPO expression was associated with the absence of 
metastases. In positive cells, TPO was located intra-cellularly without 
membrane staining, indicating an abnormal processing of the protein.  
We found a significant relationship between high Duox expression and a 
reduced thyroid cancer mortality. Similarly, in well differentiated thyroid 
carcinomas, Duox expression is related to tumor differentiation and is found in 
neoplastic tissues able to pick up radioiodine and with detectable expression of 
TPO, pendrin and sodium iodide symporter (De Micco 1994, Caillou 2001). 
These results suggest that persistent functional differentiation indicates a less 
aggressive behavior. 
For cell cycle markers, expression of cyclins A, B1 and E was found in more 
than 70% of tumors, in accordance with previous reports. However, no 
significant differences were observed between patients with and without distant 
metastases. We do not confirm the low nuclear expression of cyclin E and p27 
that was reported in papillary and undifferentiated carcinoma (Pickett 2005).  
P53 staining was positive in 50% of PDFC studied, in accordance with 
previous reports (Pollina et al 1996, Saltman 2006). However, no significant 
correlation between P53 expression and aggressiveness was found in our 
patients. 
Ki 67, a nuclear protein expressed throughout the cell cycle, but not in the G0 
or early G1 phase, is an important prognostic indicator in various types of 
tumors and is over-expressed in undifferentiated thyroid carcinoma (Saiz 
2002). In our series of PDFC, Ki67 staining was positive in 72% of tumors but 
was relatively low in most positive tumors, being higher than 10% in only 30% 
of tumors. It was not different between patients with and without distant 
metastases, and high Ki67 labeling index was not associated with a shorter 
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survival rate.  
In the multivariate analysis of immunohistochemical parameters, EGFR and 
VEGF expressions were frequently strongly expressed, but their expression had 
no prognostic significance. Vascular endothelial growth factor (VEGF) is one 
of the major pro-angiogenic factors in thyroid tumors and inhibitors of VEGF 
or of VEGFR reduce the growth of FTC xenografts (Soh 1997, Younes 2005). 
EGFR is a trans-membrane cell-surface glycoprotein that stimulates follicular 
cell proliferation and enhance thyroid cancer invasiveness (Carpenter and 
Cohen 1990, Ullrich and Schlessinger 1990, Aaronson 1991). An increased 
expression of EGFR has been found in poorly and undifferentiated thyroid 
carcinomas (Hoelting 1994, Aasland  1990, Schiff 2004, van der Laan 1995, 
Westermark 1996, Akslen 1993), and EGFR inhibitors inhibit the growth of 
anaplastic carcinoma (Schiff 2004).  
The absence of a prognostic significance of these immunohistochemical 
parameters may be related to different reasons: first, a limited number of cases 
was included in our study because of our restricted selection criteria (the 
presence of TIS growth pattern and absence of distinctive nuclear features of 
papillary carcinoma); second, we selected a series of PDFC patients with a  
homogeneous phenotype. Therefore, an elevated number of evaluated 
parameters associated to a restricted sample of PDFC could have reduced the 
statistical significance, and further studies on a wider sample of PDFC patients 
are necessary.   
It could be useful to assess other parameters by immunohistochemistry. 
Interestingly, in a recent study, this technique has helped shown an inverse 
relationship between TSH-receptor expression and proliferative activity in 
PDFC (Matsumoto et al 2008). Moreover, other studies have found a bcl-2 
expression in advanced thyroid carcinoma (Pollina L 1996) with a very intense 
staining in insular areas (Pestereli HF 2001).  
Therefore, since the absence of iodine uptake is a major prognostic indicator 
(Volante 2008) and our patients without metastasis showed a normal iodine 
uptake, it would be interesting to evaluate the expression of other proteins 
involved in iodine metabolism (NIS, Pendrin, hAIT) by 
immunohistochemistry.  
Additionally, techniques of investigation other than immunohistochemistry 
should also be performed in PDFC. For example, although it is generally 
accepted that PDFC may arise either from pre-existing well differentiated 
thyroid carcinoma or de novo, specific genetic pathways in PDFC have not 
been clear; therefore, mutational analyses of different genes involved in thyroid 
tumorigenesis could be an interesting approach. Different studies suggest that  
FTCs develop through two distinct and virtually non overlapping molecular 
pathways initiated by either RAS point mutations or PAX8-PPARγ 
rearrangement.  
The RAS gene family is comprised of three members (H-, K-, N-ras), which 
encode G-proteins involved in the signal transduction of various growth factor 
receptors. RAS gene point mutations were detected in 55-62% of PDFC (Pilotti 
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et al 1997, Garcia-Rostan et al 2003) with a significant link between RAS 
alterations and loss of thyroid tumor differentiation (Garcia-Rostan et al 2003) 
by the inhibition of thyroid-specific genes such as thyroid transcription factor-1 
(TTF1), an activator of Tg promoter transcription (Dai et al 1996) and PAX-8, 
an activator of both TPO and Tg promoter transcriptions. Moreover, normal 
follicular cells transfected with a mutant ras gene showed reduced or abolished 
differentiation markers such as thyroglobulin, TPO and NIS (Francis-Lang et al 
1992, Portella et al 1999).  
A chromosomal translocation that fuses PAX-8 with PPARγ and causes 
expression of PAX8-PPARγ fusion protein (PPFP) was found in FTC 
(Cheung L et al 2003, Dwight T et al 2003, Lacroix L et al 2005).  PAX8-
PPARγ seemed to stimulate the transcription of TPO and NIS promoters but  
failed to stimulate the transcription from the thyroglobulin promoter and 
blocked the synergistic stimulation by wild-type PAX8 and thyroid 
transcription factor-1 (Au et al 2006). Moreover, both TTF-1 and PAX8 
mRNA expressions were absent in undifferentiated thyroid carcinoma (Fabbro 
et al 1994). Therefore, these results may insinuate a role of mutant RAS or 
PAX-8- PPARγ in thyroid tumor dedifferentiation and development of PDFC 
and hypothesize a possible prognostic value of these genetic changes in 
PDFC.  
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 6. CONCLUSIONS 
 
Our study confirms that PDFC had has a more aggressive behavior than well 
differentiated thyroid carcinoma with a clinical course intermediate between the 
indolent course of well differentiated thyroid carcinoma and the aggressive course 
of undifferentiated carcinoma. Moreover, in our study the survival rate was 
similar with that of a retrospective study of PDFC defined by the presence of 
mitosis and necrosis (Hiltzik et al 2006). This similarity underlie the aggressive 
behavior of PDC independently if they are defined on basis of  growth pattern 
and/or histological grade. These data also confirm that PDFC are a different 
entity with a clinical outcome worse than well-differentiated thyroid 
carcinomas suggesting the necessity of a new and clear classification of these 
tumors.  
As expected, advanced age and larger tumor size are associated with an 
aggressive behaviour. Indeed, in patients older than 45 years, metastases free 
survival and overall survival rates were lower and a larger tumor size (larger 
than 4 cm) and/or the invasion of the thyroid capsule was associated with a 
higher risk of distant metastases and with a poor survival. Moreover, death 
occurred in patients with distant metastases.   
Surprisingly, in our patients detectable TPO expression was associated with the 
absence of metastases. However, in positive cells TPO was located in the 
cytoplasm suggesting an abnormal processing of the protein.  
Moreover, we found that a high expression of Duox was significantly 
associated with a reduced risk of thyroid cancer mortality, suggesting that the 
persistence of a functional differentiation indicates a less aggressive behaviour. 
Therefore, the parallel evaluations of clinical, histological and 
immunohistochemical characteristics of PDFC allow to achieve the following 
conclusions:  
• an accurate histological classification is mandatory to recognize and 
uniform PDFC diagnosis, to separate this category from well differentiated 
thyroid cancer and to regulate the treatment and follow up to tumor 
histology. 
• in PDFC the thyroid-specific enzymatic pathway, responsible of iodine 
metabolism, is severely modified and, of consequence, radioiodine 
treatment is inefficient in the majority of these tumors. 
Immunohistochemistry is useful to define the degree of expression and 
localization of many thyroid-specific proteins. In our study, 
immunohistochemical data provide prognostic information showing a high 
expression of DUOX in PDFC without metastasis.  
• immunohistochemistry is of limited usefulness to achieve a diagnosis of 
PDFC but, in future, it may have a role  to predict  response to receptor-
targeted therapy through the availability of novel cellular markers.  
 45
7. ACKNOWLEDGMENTS 
 
This study was done during a fellowship from the Italian-French University in 
collaboration  with the Institut Gustave Roussy (Villejuif), University “Paris Sud”,  
Departments of Pathology and Nuclear Medicine and Endocrine Oncology and 
with the University of Naples “Federico II”, Department of Molecular and Clinical 
Endocrinology and Oncology. 
My  special thanks go to Prof. Martin Schlumberger, who gave me the opportunity 
to work with him and his research team in Villejuif. He supported me from the 
first time I met him in Naples and during all my doctorate.  
I would like to express my gratitude at Dr. Bernard Caillou who helped me to 
know and appreciate the histological study of thyroid tumors. 
I would like thank Dr Houda Boukeris who helped me to elaborate the statistical 
analysis.  
My thanks to Prof. Giancarlo Vecchio, Coordinator of Doctorate School in 
Molecular Medicine, University of Naples Federico II. 
My special thanks go to Prof. Bernadette Biondi for her support during the whole 
period of my work. She guided me in discovering and investigating the fascinating 
field of thyroid tumors. I would like also thank Prof. Gaetano Lombardi who has 
always trusted me and my work. 
My thanks to Monique Talbot to train me laboratory and immunohistochemical 
procedures and all of the people, in Villejuif and in Naples, who offered me all of 
their experience and competence during my Doctorate.  
 46
 
 
8. BIBLIOGRAPHY 
 
1. Aaronson SA Growth factors and cancer. Science 1991; 254:1146-53 
2. Aasland R, Akslen LA, Varhaug JE, Lillehaug JR  Co-expression of the 
genes enconding transforming growth factor and its receptor in 
papillary carcinomas of the thyroid. International Journal of Cancer 
1990; 46:382-87,  
3. Akslen La, Myking AO, Salvesen H, Varhaug JE  Prognostic impact of 
EGF-receptor in papillary thyroid carcinoma. British Journal of Cancer 
1993; 63:808-12 
4. American Joint Committee on Cancer: Thyroid in: AJCC cancer 
staging handbook. 6th edition. Spinger, New York, 2002 pp89-98 
5. Ashfaq R, Vuitch F, Delgado R, Albores-Saavedra J.Papillary and 
follicular thyroid carcinomas with an insular component. Cancer 
1994;73:416-23 
6. Au AYM., McBride C,. Wilhelm KGJr, Koenig RJ, Speller B, Cheung 
L, Messina M, Wentworth J, Tasevski V, Learoyd D, Robinson BG, 
Clifton-Bligh RJ PAX8-peroxisome proliferator-activated receptor 
gamma (PPARgamma) disrupts normal PAX8 or PPARgamma 
transcriptional function and stimulates follicular thyroid cell growth. 
Endocrinology 2006; 147:367-76. 
7. Basolo F, Caligo MA, Pinchera A Cyclin D1 overexpression in thyroid 
carcinomas: relation with clinico-pathological parameters, 
retinoblastoma gene product and Ki67 labeling index.  Thyroid 2000; 
10:709-10 
8. Brennan MD, Bergstrahl EJ, Van Heerden JA Follicular thyroid cancer 
treated at the Mayo Clinic, 1976 through 1970: initial manifestations, 
pathologic findings, therapy and outcome. Mayo Clinic Proceedings 
1991;666:11-22 
9. Caillou B, Dupuy C, Lacroix L, Nocera M, Talbot M, Ohayon M, 
Deme D, Bidart JM, Schlumberger M, Virion A, Expression of reduced 
nicotinamide adenine dinucleotide phosphate oxidase (ThoX, LNOX, 
Duox) genes and proteins in human thyroid tissues. The Journal of 
clinical endocrinology and metabolism 2001; 86:3351-58. 
10. Carcangiu ML, Zampi G, Rosai J Poorly differentiated (“insular”) 
thyroid carcinoma The American journal of surgical pathology 1984; 
9:655-68. 
11. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 
265:7709-12,  
12. Chen H, Nicol T, Zeiger M et al Hürthle cell neoplasms of the thyroid. 
Are there factors predictive of malignancy? Annals of surgery 1998; 227: 
542-46. 
 47
13. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, 
Wentworth J, Philips J, Clifton-Bligh R, Robinson BG: Detection of the 
PAX8-PPAR gamma fusion oncogene in both follicular thyroid 
carcinomas and adenomas. The Journal of clinical endocrinology and 
metabolism 2003, 88:354-357 
14. Clauss M. Molecular biology of the VEGF and the VEGF receptor 
family. Seminars in thrombosis and hemostasis 2000;26: 561-69. 
15. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ 
Mazzaferri EL, McIver B, Sherman SI, Tuttle RM Management 
guidelines for patients with thyroid nodules and differentiated thyroid 
cancer Thyroid 2006;16:1-33. 
16. Cornil I, Kerbel RS, Dennis JW. Tumor cell surface 1 4-linked 
galactose binds to lectin(s) on microvascular endothelial cells and 
contributes to organ colonization. The Journal of cell biology 1990; 
111: 773-81.  
17. Cox DR  Regression models and life-tables. J R Statist Soc  1972; 
34:187-220.  
18. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid 
iodide transporter. Nature. 1996;379:458-60 
19. D'Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, 
Siperstein AE, Duh QY, Clark OH. Follicular thyroid carcinoma: 
histology and prognosis. Cancer 2004; 100:1123-9. 
20. De Micco C, Vasko V, Garcia S, Zoro P, Denizot A, Henry JF. Fine-
needle aspiration of thyroid follicular neoplasm: diagnostic use of 
thyroid peroxidase immunocytochemistry with monoclonal antibody 
47. Surgery. 1994;116:1031-35 
21. De Micco C, Zoro P, Garcia S, Skoog L, Tani EM, Carayon P, Henry 
JF. Thyroid peroxidase immunodetection as a tool to assist diagnosis of 
thyroid nodules on fine-needle aspiration biopsy. European journal of 
endocrinology 1994;131:474-79.  
22. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle 
regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the 
bladder correlates with tumor grade and patient survival The American 
journal of pathology 1999;155:1129-36 
23. DeLellis RA, LLoyd R, Heitz PU, editors. WHO Classification of 
Tumors, Pathology and Genetics-Tumors of Endocrine Organs. Lyon: 
IARC Press; 2004: p1205-10. 
24. Dwight T, Thoppe SR, Foukakis T, Lui WO, Wallin G, Hoog A, Frisk 
T, Larsson C, Zedenius J. Involvement of the PAX8/peroxisome 
proliferator-activated receptor gamma rearrangement in follicular 
thyroid tumors. Journal of clinical endocrinology and metabolism 2003; 
88:4440-45 
25. Emerick GT, Duh QY, Siperstein AE, Burrow GN, Clark OH. 
Diagnosis, treatment, and outcome of follicular thyroid carcinoma. 
Cancer 1993; 72:3287-95. 
 48
26. Fabbro D, Di Loreto C, Beltrami CA, Belfiore A, Di Lauro R, Damante 
G.Expression of thyroid-specific transcription factors TTF-1 and PAX-
8 in human thyroid neoplasms. Cancer research 1994;54:4744-9. 
27. Francis-Lang H, Zannini M, De Felice M, Berlingieri MT, Fusco A, Di 
Lauro R. Multiple mechanisms of interference between transformation 
and differentiation in thyroid cells. Molecular and cellular biology 
1992;12:5793-800. 
28. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu 
R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with 
aggressive tumor phenotypes and poor prognosis in thyroid cancer. 
Journal of clinical oncology. 2003; 21:3226-35. 
29. Grebe SK, Hay I Follicular thyroid cancer. Endocrinology and 
metabolism clinics of North America 1995; 24: 761-801 
30. Hendinger C, Williams ED Sobin LH Histological typing of thyroid 
tumours. International histological classification of tumors. WHO 
vol.11, Second edition, Springer-Verlag, Berlin1988; p 25-35 
31. Hermanek P, Sobin LH. Thyroid gland. TNM classification of 
malignant tumors, 4th edition, 2nd revision, International Union Against 
Cancer, Berlin, Springer-Verlag, 1992 
32. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, Shah JP, 
Dingh B, Ghossein RA poorly differentiated thyroid carcinomas defined 
on the basis of mitosis and necrosis  Cancer 2006; 106: 1286-94 
33. Hoelting T, Buhr HJ, Herfarth C.Intraoperative tumour classification in 
papillary thyroid cancer--a diagnostic dilemma. European journal of 
surgical oncology 1995;21:353-6. 
34. Hoelting T, Siperstein AE, Clark OH, Duh Qy 1994 Epidermal growth 
factor enhances proliferation, migration and invasion of follicular and 
papillary thyroid cancer in vitro and in vivo. The Journal of Clinical 
Endocrinology and Metabolism 79:401-8.  
35. Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 
and Mac-2-binding protein mediate cell-cell adhesion Cancer research 
1996; 56: 4530-4. 
36. Ito Y, Yoshida H, Nakano K et al Expression of G2-M modulators in 
thyroid neoplasms: correlation of cyclin A, B1 and cdc2 with 
differentiation. Pathology, research and practice 2002;198:397-402. 
37.  Kaplan EL, Meier P Non parametric estimation from incomplete 
observations. Journal of the American Statistical Association 1958; 
53:457-81. 
38. Khoo ML, Beasley NJ, Ezzat S, Freeman JL, Asa SL. Overexpression 
of cyclin D1 and underexpression of p27 predict lymph node metastases 
in papillary thyroid carcinoma. Journal of clinical endocrinology and 
metabolism 2002;87:1814-8 
39. Krohmn K, Stricker I, Emmrich P et al Cold thyroid nodules show a 
marked increase in proliferation markers Thyroid 2003;13:569-75. 
 49
40. Lacroix L, Lazar V, Michiels S, Ripoche H, Dessen P, Talbot M, 
Caillou B, Levillain JP, Schlumberger M,  Bidart JM| Follicular 
Thyroid Tumors with the PAX8-PPAR 1 Rearrangement Display 
Characteristic Genetic Alterations American Journal of Pathology. 
2005;167:223-31. 
41. Lacroix L, Nocera M, Mian C, Caillou B, Virion A, Dupuy C, Filetti S, 
Bidart JM, Schlumberger M Expression of nicotinamide adenine 
dinucleotide phosphate oxidase flavoprotein Duox genes and proteins in 
human papillary and follicular thyroid carcinomas Thyroid  
2001;11:1017-23. 
42. Lang W, Chrotz H, Hundeshang H Risk factors in follicular thyroid 
carcinomas. A retrospective follow-up study covering a 14-year period 
with emphasis on morphological findings. The American journal of 
surgical pathology 1986;10:246-55. 
43. Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione 
G, Nardi F, Colletta G.Cyclin D1 and Cyclin E expression in malignant 
thyroid cells and in human thyroid carcinomas. International journal of 
cancer 1998;76:806-11. 
44. Lodish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P, Darnell J, 
Molecular Cell Biology, 3d ed. 1995 Scientific American Books: p12-
20. 
45. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. Pathological tumor-
node metastasis (pTNM) staging for papillary and follicular thyroid 
carcinomas: a retrospective analysus of 700 patients. Journal of clinical 
endocrinology and metabolism 1997; 82:3553-62. 
46. Lotan R, Matsushita Y, Ohannesian D, Carralero D, Ota DM,  Cleary 
KR, Nicolson GL, Irimura T. Lactose-binding lectin expression in 
human colorectal carcinomas. Relation to tumor progression 
Carbohydrate research 1991;213:47-57. 
47. Matsumoto H, Sakamoto A, Fujiwara M, Yano Y, Shishido-Hara Y, 
Fujioka Y, Kamma H. Decreased expression of the thyroid-stimulating 
hormone receptor in poorly-differentiated carcinoma of the thyroid. 
Oncology reports 2008;19:1405-11. 
48. Mazzaferri EL, Management of a solitary thyroid nodule The New 
England journal of medicine 1993, 328:553-59. 
49. Mazzaferri EL, Young R, Oertel JE, Kenimerer WT, Page CP Papillary 
thyroid carcinoma: the impact in 576 patients. Medicine 1977; 56:171-
96. 
50. Nikiforov YE Genetic alterations involved in the transition from well-
differentiated to poorly differentiated and anaplasic thyroid carcinomas. 
Endocrine Pathology 2004;15: 319-27. 
51. Nikiforov YE, Erickson LE, Nikiforova MN, et al. Solid variant of 
papillary thyroid carcinoma: incidence, clinical-pathological 
characteristics, molecular analysis, and biological behavior. The 
American journal of surgical pathology 2001;25:1478-84.  
 50
52. Nishida T, Katayama S, Tsujimoto M, et al. Clinicopathological 
significance of poorly differentiated thyroid carcinoma. The American 
journal of surgical pathology 1999;23:205-11.  
53. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit J WA, Wiersinga 
W and the European Thyroid Cancer Taskforce. European consensus 
for the management of patients with differentiated thyroid carcinoma of 
the follicular epithelium European Journal of Endocrinology 
2006;154:787–803 
54. Pagano L, Klain M, Pulcrano M, Angellotti G, Fasano F, Salvatore M, 
Lombardi G, Biondi B. Follow-up of differentiated thyroid carcinoma. 
Minerva Endocrinology 2004;29:161-74. 
55. Papotti M, Botto Micca F, Favero A, Palestini N, Bussolati G Poorly 
differentiated thyroid carcinomas with primordial cell component. A 
group of aggressive lesions sharing insular, trabecular, and solid 
patterns. The American journal of surgical pathology 1993;17:291-301.  
56. Papotti M, Bussolati G Papillary and follicular thyroid carcinomas with 
an insular component. Cancer 1994;74:2599-600. 
57. Parkin DM, Whelan SJ, Ferlay J Cancer incidence in five continents, 
Vol.7 IARC Scientific Publication 143, International Agency of 
Research on Cancer, Lyon 1997; p1300-05. 
58. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, 
Mantel N, McPherson K, Peto J, Smith PG Design and analysis of 
randomized clinical trials requiring prolonged observation of each 
patient. II. analysis and examples. British Journal of Cancer 1977;35:1-
39. 
59. Pickett CA, Agoff SN, Widman TJ, Bronner MP Altered expression of 
cyclins and cell cycle inhibitors in the papillary thyroid cancer: 
prognostic implications. Thyroid 2005; 15:461-73. 
60. Pilotti S, Collini P, Mariani L, et al. Insular carcinoma: a distinct de 
novo entity among follicular carcinomas of the thyroid gland. The 
American journal of surgical pathology 1997;21:1466-73. 
61. Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F. 
bcl-2, p53 and proliferating cell nuclear antigen expression is related to 
the degree of differentiation in thyroid carcinomas. British journal of 
cancer 1996;73:139-43. 
62. Portella G, Vitagliano D, Borselli C, Melillo RM, Salvatore D, 
Rothstein JL, Vecchio G, Fusco A, Santoro M. Human N-ras, TRK-T1, 
and RET/PTC3 oncogenes, driven by a thyroglobulin promoter, 
differently affect the expression of differentiation markers and the 
proliferation of thyroid epithelial cells.  Oncology research. 
1999;11:421-7. 
63. Rosai J, Carcangiu ML, De Lellis RA Tumors of the thyroid gland. Atlas 
of tumor pathology. AFIP Third series 1995, fascicle 5: p20-35. 
64. Rufini V, Salvatori M, Fadda G, Pinnarelli L, Castaldi P, Maussier ML, 
Galli G.Thyroid carcinomas with a variable insular component: 
 51
prognostic significance of histopathologic patterns. Cancer 
2007;110:1209-17. 
65. Saiz AD, Olvera M, Rez KS and al Immunohistochemical expression of 
cyclin D1, E2F-1 and Ki-67 in benign and malignant thyroid lesions. 
The Journal of pathology 2002;198: 157-62 
66. Sakamoto A, Kasai N, Sugano H Poorly differentiated carcinoma of the 
thyroid. A clinico-pathologic entity for a high risk group of papillary 
and follicular carcinomas. Cancer 1983;52:1849-55. 
67. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth 
factor-related peptides and their receptors in human malignancies. 
Critical reviews in oncology/hematology 1995;19 (3):183-232. 
68. Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi 
OG, Kim S, Zhou G, Mandal M, Bekele BN, Holsinger FC, Sherman 
SI, Yeung SC, El-Naggar AK, Myers JN. Epidermal growth factor 
receptor (EGFR) is overexpressed in anaplastic thyroid cancer and the 
EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid 
cancer. Clinical Cancer Research 2004; 15: 8594-602.  
69. Schroder S, Bocker W. Clear cell carcinomas of the thyroid gland/ 
clinicopathological study of 13 cases; Histopathology 1986;10:75-89. 
70. Sionov RV, Hayon IL, Haupt Y The Regulation of p53 Growth 
Suppression In Blagosklonny MV, editor. Cell Cycle Checkpoints and 
Cancer. National Cancer Institute, Bethesda 2002; p1300-05. 
71. Soh EY, Duh QY, Sobhi SA, Young DM, Epstein HD, Wong MG, 
Garcia YK, Min YD, Grossman RF, Siperstein AE, Clark OH. Vascular 
endothelial growth factor expression is higher in differentiated thyroid 
cancer than in normal or benign thyroid. Journal of clinical 
endocrinology and metabolism 1997;82:3741-7. 
72. Takano Y, Kato Y, van Diest PJ, Masuda M, Mitomi H, Okayasu I 
Cyclin D2 overexpression and lack of p27 correlate positively and 
cyclin E inversely with a poor prognosis in gastric cancer cases. The 
American journal of pathology 2000;156:585-94. 
73. Ullrich A, Schlessinger J. Signal transduction by receptors with 
tyrosine kinase activity. Cell 1990; 61:203-12.  
74. van der Laan BF, Freeman JL, Asa SL. Expression of growth factors 
and growth factor receptors in normal and tumorous human thyroid 
tissues. Thyroid 1995; 5:67-73.  
75. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, Katoh R, 
Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, Bussolati G, 
Rosai J. Poorly differentiated thyroid carcinoma: the Turin proposal for 
the use of uniform diagnostic criteria and an algorithmic diagnostic 
approach. The American journal of surgical pathology. 2007;31:1256-
64. 
76. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, 
Torchio B, Papotti MG. Poorly differentiated carcinoma of the thyroid 
with trabecular, insular and solid patterns. A clinical-pathologic study 
 52
of 183 patients. Cancer 2004,100:950-7. 
77. Weber KB, Shroyer KR, Heinz De et al The use of a combination of 
galectin-3 and thyroid peroxidase for the diagnosis and prognosis of 
thyroid cancer. American journal of clinical pathology 2004;122:524-
31. 
78. Weber KB, Shroyer KR, Heinz DE, Nawaz S, Said MS, Haugen BR. 
The use of a combination of galectin-3 and thyroid peroxidase for the 
diagnosis and prognosis of thyroid cancer. American journal of clinical 
pathology 2004;122:524-31. 
79. Westermark K, Lundqvist M, Wallin G, Dahlman T, Hacker GW, 
Heldin NE, Grimelius L EGF-receptors in human normal and 
pathological thyroid tissue. Histopathology 1996; 28:221-7. 
80. Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne 
VS, Yazici YD, Mandal M, Bekele BN, Bucana CD, Fidler IJ, Myers 
JN. Antivascular therapy of human follicular thyroid cancer 
experimental bone metastasis by blockade of epidermal growth factor 
receptor and vascular growth factor receptor phosphorylation. Cancer 
research 2005;65:4716-27. 
 53
 
LIST OF PUBLICATIONS 
 
This dissertation is based upon the following publications: 
 
1. Pagano L, Klain M, Pulcrano M, Angellotti G, Fasano F, Salvatore M, 
Lombardi G, Biondi B. Follow-up of differentiated thyroid carcinoma. 
Minerva Endocrinol. 2004 Dec;29(4):161-74. 
 
2. Pulcrano M Boukheris H, Talbot M, Caillou B, Dupuy C, Virion A, De 
Vathaire F, Schlumberger M. Poorly differentiated follicular thyroid 
carcinoma: prognostic factors and relevance of histological 
classification. Thyroid. 2007 Jul;17(7):639-46. 
 
3. Biondi B, Pulcrano M, Pagano L, Lombardi G Adjuvant treatment 
with thyrotopin alfa for remnant ablation in thyroid cancer Biologics: 
Targets & Therapy in press 
 54
 55
 56
 57
 58
 59
 60
 61
 
 
 
 
 
 62
 63
 
 64
 65
 66
 67
 68
 69
 
 70
 
 71
 72
 73
 
 74
 
 
 
